1clo
From Proteopedia
(New page: 200px<br /> <applet load="1clo" size="450" color="white" frame="true" align="right" spinBox="true" caption="1clo, resolution 2.1Å" /> '''ANTI-CARCINOEMBRYONI...) |
|||
| Line 1: | Line 1: | ||
| - | [[Image:1clo.gif|left|200px]]<br /> | + | [[Image:1clo.gif|left|200px]]<br /><applet load="1clo" size="350" color="white" frame="true" align="right" spinBox="true" |
| - | <applet load="1clo" size=" | + | |
caption="1clo, resolution 2.1Å" /> | caption="1clo, resolution 2.1Å" /> | ||
'''ANTI-CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY A5B7'''<br /> | '''ANTI-CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY A5B7'''<br /> | ||
==Overview== | ==Overview== | ||
| - | The crystal structures of two pairs of Fab fragments have been determined. | + | The crystal structures of two pairs of Fab fragments have been determined. The pairs comprise both a murine and an engineered human form, each derived from the antitumor antibodies A5B7 and CTM01. Although antigen specificity is maintained within the pairs, antigen affinity varies. A comparison of the hypervariable loops for each pair of antibodies shows their structure has been well maintained in grafting, supporting the canonical loop model. Detailed structural analysis of the binding sites and domain arrangements for these antibodies suggests the differences in antigen affinity observed are likely to be due to inherent flexibility of the hypervariable loops and movements at the VL:VH domain interface. The four structures provide the first opportunity to study in detail the effects of protein engineering on specific antibodies. |
==About this Structure== | ==About this Structure== | ||
| - | 1CLO is a [http://en.wikipedia.org/wiki/Protein_complex Protein complex] structure of sequences from [http://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http:// | + | 1CLO is a [http://en.wikipedia.org/wiki/Protein_complex Protein complex] structure of sequences from [http://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1CLO OCA]. |
==Reference== | ==Reference== | ||
| Line 14: | Line 13: | ||
[[Category: Mus musculus]] | [[Category: Mus musculus]] | ||
[[Category: Protein complex]] | [[Category: Protein complex]] | ||
| - | [[Category: Banfield, M | + | [[Category: Banfield, M J.]] |
| - | [[Category: Brady, R | + | [[Category: Brady, R L.]] |
| - | [[Category: King, D | + | [[Category: King, D J.]] |
[[Category: Mountain, A.]] | [[Category: Mountain, A.]] | ||
[[Category: fab-fragment]] | [[Category: fab-fragment]] | ||
[[Category: immunoglobulin]] | [[Category: immunoglobulin]] | ||
| - | ''Page seeded by [http:// | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 12:07:18 2008'' |
Revision as of 10:07, 21 February 2008
|
ANTI-CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY A5B7
Overview
The crystal structures of two pairs of Fab fragments have been determined. The pairs comprise both a murine and an engineered human form, each derived from the antitumor antibodies A5B7 and CTM01. Although antigen specificity is maintained within the pairs, antigen affinity varies. A comparison of the hypervariable loops for each pair of antibodies shows their structure has been well maintained in grafting, supporting the canonical loop model. Detailed structural analysis of the binding sites and domain arrangements for these antibodies suggests the differences in antigen affinity observed are likely to be due to inherent flexibility of the hypervariable loops and movements at the VL:VH domain interface. The four structures provide the first opportunity to study in detail the effects of protein engineering on specific antibodies.
About this Structure
1CLO is a Protein complex structure of sequences from Mus musculus. Full crystallographic information is available from OCA.
Reference
VL:VH domain rotations in engineered antibodies: crystal structures of the Fab fragments from two murine antitumor antibodies and their engineered human constructs., Banfield MJ, King DJ, Mountain A, Brady RL, Proteins. 1997 Oct;29(2):161-71. PMID:9329081
Page seeded by OCA on Thu Feb 21 12:07:18 2008
